Literature DB >> 25557722

Survivorship.

Douglas J Harrison1, Cindy Schwartz.   

Abstract

Significant therapeutic advances for soft tissue sarcomas allow increasing numbers of patients--adult and pediatric--to achieve long term survival. However, the harsh cytotoxic therapies are responsible for adverse physical and psychosocial effects that require long-term follow-up care, specific to survivorship issues. In the adult and pediatric patient population, guidelines for care developed by experts in comprehensive survivorship clinics are evolving to assist the practitioner while on-line supports bring information directly to the survivors.
© 2014 Wiley Periodicals, Inc.

Entities:  

Keywords:  follow-up; late effects; long-term; sarcoma; survival

Mesh:

Year:  2014        PMID: 25557722     DOI: 10.1002/jso.23844

Source DB:  PubMed          Journal:  J Surg Oncol        ISSN: 0022-4790            Impact factor:   3.454


  6 in total

1.  Evaluating the Impact of Surveillance Follow-Up Intervals in Patients Following Resection of Primary Well-Differentiated Liposarcoma of the Retroperitoneum.

Authors:  Emily Z Keung; Nikita Rajkot; Keila E Torres; Neeta Somaiah; Kelly K Hunt; Barry W Feig; Christopher P Scally; Naruhiko Ikoma; Christina L Roland
Journal:  Ann Surg Oncol       Date:  2020-05-14       Impact factor: 5.344

2.  Targeting Anaplastic Lymphoma Kinase (ALK) in Rhabdomyosarcoma (RMS) with the Second-Generation ALK Inhibitor Ceritinib.

Authors:  Anke E M van Erp; Melissa H S Hillebrandt-Roeffen; Laurens van Houdt; Emmy D G Fleuren; Winette T A van der Graaf; Yvonne M H Versleijen-Jonkers
Journal:  Target Oncol       Date:  2017-12       Impact factor: 4.493

3.  In Vivo Bioorthogonal Chemistry Enables Local Hydrogel and Systemic Pro-Drug To Treat Soft Tissue Sarcoma.

Authors:  Jose M Mejia Oneto; Irfan Khan; Leah Seebald; Maksim Royzen
Journal:  ACS Cent Sci       Date:  2016-07-13       Impact factor: 14.553

4.  Expression and clinical association of programmed cell death-1, programmed death-ligand-1 and CD8+ lymphocytes in primary sarcomas is subtype dependent.

Authors:  Anke E M van Erp; Yvonne M H Versleijen-Jonkers; Melissa H S Hillebrandt-Roeffen; Laurens van Houdt; Mark A J Gorris; Laura S van Dam; Thomas Mentzel; Marije E Weidema; C Dilara Savci-Heijink; Ingrid M E Desar; Hans H M Merks; Max M van Noesel; Janet Shipley; Winette T A van der Graaf; Uta E Flucke; Friederike A G Meyer-Wentrup
Journal:  Oncotarget       Date:  2017-07-07

5.  Considerations for the Long Term Treatment of Pediatric Sarcoma Survivors.

Authors:  Kurt R Weiss; Melissa N Zimel
Journal:  Indian J Orthop       Date:  2018 Jan-Feb       Impact factor: 1.251

Review 6.  Therapeutic Approaches Targeting PAX3-FOXO1 and Its Regulatory and Transcriptional Pathways in Rhabdomyosarcoma.

Authors:  Thanh Hung Nguyen; Frederic G Barr
Journal:  Molecules       Date:  2018-10-28       Impact factor: 4.411

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.